Physician profile
Dylan Shockley
NPI 1588295836
$2,959.05
in general payments reported to CMS, 2019-2025
22 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $1,224 · 2023: $432 · 2024: $405 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.64 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $773.85 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.37 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $424.41 | 2021-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $218.80 | 2021-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $162.59 | 2021-2024 | |
| Celgene Corporation | $126.24 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $125.41 | 2021-2022 | |
| Qol Medical, LLC | $105.52 | 2021-2023 | Sucraid |
| La Jolla Pharmaceutical Company | $94.20 | 2021 | |
| Daiichi Sankyo INC. | $78.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.67 | 2021 | |
| Ardelyx, INC. | $37.82 | 2022-2023 | Ibsrela |
| Genzyme Corporation | $37.46 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $33.05 | 2021-2022 | |
| Lilly USA, LLC | $31.89 | 2024 | Omvoh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.15 | 2022 | |
| Intercept Pharmaceuticals, INC. | $27.06 | 2021-2022 | |
| Organon LLC | $26.00 | 2024 | |
| Baxter Healthcare | $22.25 | 2025 | Perclot |
| Aimmune Therapeutics, INC. | $18.51 | 2025 | Zenpep |
| Sandoz INC. | $17.96 | 2023 | Hyrimoz |
| Boston Scientific Corporation | $15.68 | 2025 | Cre Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Shockley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.